Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02425592 · ClinicalTrials.gov registry record
Active Surveillance in Prostate Cancer, Imaging to Detect Radiographic Progression as an Endpoint (ASPIRE)
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 223
- Enrollment target
NCT02425592: Completed study, sponsored by Yale University.
NCT02425592 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 223 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02425592 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 223 participants
- Enrollment target
Study Summary
The objective in this study is to determine if MRI-identified progression can decrease frequency or need for repeated prostate biopsy in men on active surveillance (AS). Our hypothesis is that MRI alone is adequate to detect progression of prostate cancer in men on active surveillance (AS) after a MRI-US fusion prostate biopsy.
Primary Outcome
MRI-US Fusion biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2015-04 |
| Est. Completion | 2025-05 |
What the finished NCT02425592 record still lists
NCT02425592 is an observational study that tracks outcomes without assigning an intervention. The registered 223 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02425592 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02425592 about?
NCT02425592 is a clinical study titled "Active Surveillance in Prostate Cancer, Imaging to Detect Radiographic Progression as an Endpoint (ASPIRE)". The objective in this study is to determine if MRI-identified progression can decrease frequency or need for repeated prostate biopsy in men on active surveillance (AS). Our hypothesis is that MRI alone is adequate to detect progression of prostate cancer in men on active surveillance (AS) after a ...
What is the current status of trial NCT02425592?
This trial is currently completed. The enrollment target is 223 participants. The study started on 2015-04. Estimated completion is 2025-05.
Who is sponsoring clinical trial NCT02425592?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06640803 · 223 participants · NA
Sacramento Clinical High Risk for Psychosis Stepped-Care Program
- NCT07175285 · 223 participants
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- NCT07205718 · 223 participants · Phase 1
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
- NCT02706561 · 224 participants · NA
Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia